Previously, Vaxzevria was given a conditional Marketing Authorisation (cMA) due to the critical nature of the COVID-19 pandemic, and as further significant evidence of safety and efficacy benefits of Vaxzevria have been confirmed, the EMA has decided to grant a full MA.
The green light from the EMA follows the positive recommendation from its branch, the Committee for Medicinal Products for Human Use (CHMP), for a full MA.
The MA includes the use of Vaxzevria in both a primary vaccination series, and as both a heterologous – with an approved mRNA COVID-19 vaccine – or homologous – all the same vaccine – third dose booster…
